

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/172030/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Hunt, Megan, Underwood, Jack , Hubbard, Leon and Hall, Jeremy 2024. Risk of physical health comorbidities in autistic adults: a clinical nested cross-sectional study. *BJPsych Open* 10.1192/bjo.2024.777

Publishers page:

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# Risk of physical health comorbidities in autistic adults: a clinical nested cross-sectional study

Megan Hunt <sup>\*1,2</sup>, Jack F G Underwood <sup>\*2</sup>, Leon Hubbard <sup>3</sup>, Jeremy Hall <sup>2</sup>

<sup>1</sup> North Bristol NHS Trust, Bristol, UK

<sup>2</sup> Neuroscience & Mental Health Innovation Institute, Division for Psychological Medicine and Clinical Neuroscience, Cardiff University, UK

<sup>3</sup> National Centre for Mental Health, Division for Psychological Medicine and Clinical Neuroscience, Cardiff University, UK

\* Indicates Joint First Author

Correspondence to Jack Underwood, [underwoodj4@cardiff.ac.uk](mailto:underwoodj4@cardiff.ac.uk)

## Abstract

**Background:** Physical health conditions are more common in autistic individuals. Some, like epilepsy, have considerable evidence supporting their increased prevalence, but many diseases lack literature to make strong conclusions.

**Aims:** To investigate the prevalence of physical health comorbidities in autism.

**Method:** We undertook a nested cross-sectional study using a sample from the National Centre for Mental Health (NCMH) database. It included participants from England and Wales who reported a clinician-made diagnosis of autism (n = 813) and a control sample without autism or mental illness (n = 2,781). Participants had provided a medical history at enrolment. Analysis was carried out by binomial logistic regressions controlling for age, sex, smoking status, antipsychotic and mood stabiliser use. Sub-analysis of individuals with concurrent intellectual disability (n = 86) used binomial logistic regression with the same control variables.

**Results:** Many physical health conditions were significantly more common in autism. 16 of 28 conditions showed increased odds, with the highest odds ratios observed for liver disease, COPD, kidney disease, osteoporosis and rheumatoid arthritis. Sub-analysis demonstrated a similar pattern of physical health in autistic individuals with and without concurrent intellectual disability. Some

30 conditions, including osteoporosis, hyperthyroidism, head injury and liver disease had larger odds  
31 ratios in individuals with concurrent intellectual disability.

32 **Conclusions:** Physical health conditions occur more commonly in autistic individuals and certain  
33 conditions are further increased in those with concurrent intellectual disability. Our findings  
34 contribute to prior evidence, including novel associations, and suggest autistic individuals are at  
35 greater risk of physical health problems throughout adulthood.

36

### 37 Introduction

38 Autism spectrum disorder, (hereafter 'autism' or 'autistic', reflecting reported community  
39 preference for identity-first language<sup>1</sup>) is a neurodevelopmental condition that is characterised by  
40 behavioural and social communication features. It is a common condition, with a reported  
41 prevalence of approximately 1%<sup>2</sup>, and has a male-to-female ratio of about 3:1<sup>3</sup>. There is much  
42 research into psychiatric comorbidities in autism, showing a high burden of co-occurring mental  
43 health conditions<sup>4</sup>, however, research into physical health conditions is more limited. A recent  
44 umbrella systematic review suggests that there is an increased prevalence of physical conditions in  
45 autism, but this paper also serves to highlight vast gaps in the literature, with no adequate  
46 systematic reviews on many major conditions, such as heart disease<sup>5</sup>. Many large database studies  
47 similarly allow us to conclude higher rates of physical health conditions in the autistic community,  
48 finding increased prevalence of conditions such as gastrointestinal disorders, neurological disorders  
49 (e.g. epilepsy), diabetes, thyroid disorders and metabolic disorders (e.g. dyslipidaemia)<sup>6-12</sup>, however  
50 we are limited in our ability to make conclusions about specific health conditions, as many are not  
51 well studied. Epilepsy is the most well-researched physical condition in autism with multiple meta-  
52 analyses and individual studies documenting increased odds compared to controls or the general  
53 population (often with large odds ratios)<sup>6-8,11-14</sup>, and findings suggest that those who are female or  
54 have concurrent intellectual disability (ID) are at an even greater risk<sup>15,16</sup>. Considering  
55 gastrointestinal disorders, one meta-analysis finds increased odds of constipation, diarrhoea and  
56 abdominal pain in autistic children<sup>17</sup>, another finds that autistic adults are more likely to have many  
57 conditions, such as IBS, hernias, gallbladder disease and chronic constipation<sup>10</sup> and multiple studies  
58 suggest inflammatory bowel disease to be more common in autism<sup>6,18,19</sup>. Several studies find  
59 increased risk of hyperlipidaemia/dyslipidaemia<sup>7,11,12,14,20</sup>, hypertension<sup>7,8,20</sup> and various heart  
60 diseases<sup>7-9,21</sup> in autistic individuals, suggesting that these could be more common, but lack of  
61 studies, or the existence of a few studies with contradictory findings<sup>9,11,14,22</sup> preclude strong  
62 conclusions. Autoimmune diseases seem to be more common in autistic individuals<sup>7,23</sup> and autism

63 more common in those with autoimmune diseases<sup>24</sup>, although it is unclear from research if this  
64 applies to a select few or to all autoimmune diseases. For several conditions, much of the existing  
65 evidence is conflicting; asthma has multiple studies supporting its increased prevalence in  
66 autism<sup>9,21,25</sup>, however two recent meta-analyses conclude no association between autism and  
67 asthma<sup>26,27</sup>. A recent review of diabetes concluded uncertainty over whether it is more common in  
68 autism<sup>28</sup> and cancer shows a similarly mixed picture, with some studies showing increased<sup>8,29</sup> and  
69 some showing decreased<sup>7,12</sup> rates of cancer in autistic individuals. Most notably, conditions of old  
70 age are rarely investigated, and though one study in over-65s found increased odds of a range of  
71 age-related conditions like osteoporosis, osteoarthritis, Parkinson's disease, COPD and cognitive  
72 disorders<sup>8</sup>, and another in over-45s found increased hazard ratios for conditions including heart  
73 failure, cerebrovascular disease and COPD<sup>9</sup>, few of these results are replicated elsewhere.

74 For many conditions, gaps in the literature prevent conclusions or interpretation of underlying  
75 mechanisms. This study therefore aims to compare the physical health of individuals with and  
76 without autism using a nested cross-sectional design on a large prospectively-recruited e-cohort of  
77 individuals across a broad range of ages, to assess whether specific conditions or clusters of  
78 conditions are more common in autistic individuals.

## 79 **Methods**

### 80 *Study population and measures:*

81 The sample was drawn from the National Centre for Mental Health (NCMH) database. NCMH is a  
82 Welsh Government-funded Research Centre investigating neurodevelopmental, adult psychiatric,  
83 and neurodegenerative psychiatric disorders across the lifespan<sup>30</sup>. The cohort in the database  
84 consists of individuals aged 4 or older who have experienced or are related to someone who has  
85 experienced one of these disorders, as well as volunteer control participants who have not  
86 experienced any disorder<sup>30</sup>. Participants were recruited systematically to NCMH through disease  
87 registers, clinical note screening and identification by clinical care teams, and non-systematically  
88 through media advertisements, posters/leaflets in NHS waiting rooms, voluntary organisations and  
89 contacting of individuals involved in previous studies within the Institute of Psychological Medicine  
90 and Clinical Neurosciences<sup>30</sup>. All individuals in this study provided written informed consent after  
91 viewing the patient information sheet or, for those under 16 or lacking sufficient mental capacity,  
92 assent was provided where possible, and written consent was obtained from a nominated individual,  
93 such as the next of kin, a family member, or a carer<sup>30</sup>. Participants underwent a standardised  
94 interview establishing personal and family history of mental illness and medication profile, and were  
95 also given a standardised self-report questionnaire to complete<sup>30</sup>.

96 NCMH received a favourable ethical opinion from the Wales Research Ethics Committee 2 on 25<sup>th</sup>  
97 November 2016. This project utilised data held within the NCMH ethical approval, as part of existing  
98 questionnaires. An application for data access was made in December 2021, and approved after  
99 internal board review in January 2022. The NCMH database was interrogated and individuals were  
100 extracted for inclusion in this study if they had 1) reported having a clinical diagnosis of autism and  
101 2) had filled in any of the medical history section of the questionnaire (n = 813) (full recruitment  
102 method provided in the Supplementary Material). An unmatched control sample of individuals  
103 without autism and with no mental health or neurodevelopmental conditions (n = 2,781) was also  
104 obtained from the NCMH database. Any individuals who were completely missing health data were  
105 excluded from analysis. Where individuals had only completed part of the questionnaire, they were  
106 included in analysis for physical conditions where they had data available.

107 Following consent, trained researchers administered a standardised interview assessment to gather  
108 data on the participant's diagnostic history at enrolment to NCMH. The NCMH Brief Assessment  
109 captures information on lifetime physical health conditions in its medical history section at  
110 enrolment to NCMH, and this was used to derive the outcome measure of physical health conditions  
111 in the sample. Participants are given a list of conditions and told to indicate whether they have ever  
112 been told by a doctor or health professional that they have the condition, allowing for a binary  
113 outcome of either presence or absence of the condition. Questions on lifetime diagnosis are asked  
114 as "Has a doctor or health professional ever given you a diagnosis of [*listing a broad range of*  
115 *psychiatric and physical health conditions, one at a time, including autism*]?" Further information  
116 regarding diagnosis, symptoms, treatment, and outcomes was obtained from clinical records where  
117 appropriate consent had been obtained to do so. After assessment of the data (see Supplementary  
118 Material) 28 physical health variables were included for statistical analysis.

#### 119 *Statistical analysis:*

120 Initially, data were plotted to visualise and compare group frequencies, followed by Chi-squared test  
121 to assess the association between autism and physical health, with a significance level of 5%.

122 Binomial logistic regression was used to calculate odds ratios for each condition in autism, with a  
123 95% confidence interval. Two logistic regression models were used. The first model looked at the  
124 odds of each condition in autism and included age and sex as covariates in the model. Autism  
125 diagnosis was the independent variable and physical health diagnoses were the dependent variable.  
126 A second multivariable logistic regression model further included smoking status, mood stabiliser  
127 use and antipsychotic use, as well as age and sex as covariates, again with autism diagnosis as the  
128 independent variable and physical health diagnoses the dependent variable. These co-variables were

129 selected as known risk factors for a wide range of diseases (see Supplementary Material for  
130 explanation and citations). Though some mood stabilisers are also anticonvulsants, removing mood  
131 stabilisers as a control variable when investigating epilepsy had little effect on the odds ratio in a  
132 post-hoc assessment (see Supplementary Material), so it was deemed most appropriate to continue  
133 using the same model for all conditions.

#### 134 *Intellectual Disability Sub-analysis*

135 Additional sub-analyses were conducted to investigate the effects of ID. Binomial logistic regression  
136 models were run in which each physical health condition outcome (dependent variable) was  
137 assessed, comparing controls (n = 2781) to autistic individuals without ID (n = 727) and to autistic  
138 individuals with ID (n = 86), while controlling for age, sex, smoking status, and antipsychotic and  
139 mood stabiliser use. A direct comparison model between autism with ID and isolated autism was not  
140 utilised due to concerns around collider biases between autism and ID. In the sub-analysis, a further  
141 5 conditions were identified as having no cases amongst individuals with concurrent ID, and  
142 therefore were not modelled.

143 Benjamini-Hochberg correction was carried out to adjust for multiple hypothesis testing and reduce  
144 the chance of a type I error, with an initial  $\alpha$  of 0.05. In the main analysis, 75 tests were run (25 tests  
145 per model) and included in the correction, leading to a false discovery rate correction of 0.029. In  
146 the sub-analysis, 20 tests were run, leading to a false discovery rate correction of 0.029. Data were  
147 analysed using IBM SPSS Statistics Version 27 for Windows<sup>31</sup>.

#### 148 **Results**

149 Data were collected for 3,674 participants. After deletion of duplicates and individuals with no  
150 recorded physical health data, a total sample of 3,594 individuals remained. 813 participants met the  
151 inclusion criteria for the autism group, and these were compared to 2,781 controls.

152 The mean age in the autism sample was 33.73 (range 11-97, standard deviation (SD) 13.45). The  
153 mean age in the control sample was 49.61 (range 6-93, SD 18.74). The autism group was composed  
154 of 41.9% females, 53.3% males and 4.4% identifying as gender variant/non-conforming/transgender  
155 male/transgender female and the control group was composed of 65.8% females, 33.0% males and  
156 0.9% gender variant/non-conforming/transgender male/transgender female. The male to female  
157 ratio in the autism group was 1.27:1.

158 On initial analysis with Chi-squared test (Table 1), the autism sample was noted to have a  
159 significantly greater prevalence ( $p < 0.001$ ) of asthma (33.2% vs 16.3%), epilepsy (8.0% vs 1.8%), head  
160 injury (16.4% vs 3.2%), migraine headaches (33.2% vs 15.5%), IBD (7.2% vs 3.1%), liver disease (1.9%

161 vs 0.4%) and other autoimmune conditions (5.2% vs 2.2%) than the control sample. It was also  
162 observed that the control group had a significantly higher prevalence of cancer (6.3% vs 1.4%), heart  
163 disease (4.0% vs 1.5%), hypertension (16.7% vs 12.0%) and osteoarthritis (8.9% vs 5.5%) than the  
164 autism group. All other individual conditions showed no significant difference between the autism  
165 and control group.

166 [Insert Table 1]

167 The initial logistic regression model controlling for age and sex found increased odds of 17 of the 28  
168 physical health conditions in the autism group (Table 2). The largest odds ratios were observed for  
169 liver disease (OR 11.55, 95% CI 4.36–30.60,  $p < 0.001$ ), head injury (OR 5.03, 95% CI 3.30–7.67,  $p$   
170  $< 0.001$ ), osteoporosis (OR 5.16, 95% CI 2.37–11.25,  $p < 0.001$ ), kidney disease (OR 4.97, 95% CI 2.13–  
171 11.59,  $p < 0.001$ ) and memory loss/dementia (OR 4.93, 95% CI 1.80–13.51,  $p = 0.002$ ). All 17  
172 conditions remained significant after Benjamini-Hochberg correction.

173 The medication and smoking adjusted logistic regression model, which controlled for age, sex,  
174 smoking, antipsychotic use and mood stabiliser use, found autism increased the odds for 18 out of  
175 28 physical health conditions (the same conditions as the first model, with the addition of COPD).  
176 Only 16 remained significant after Benjamini-Hochberg correction (Table 2). In this model the  
177 greatest increase in odds ratios associated with autism were observed for liver disease (OR 10.96,  
178 95% CI 3.72 - 32.25,  $p < 0.001$ ), COPD (OR 7.42, 95% CI 1.79 - 30.77,  $p = 0.006$ ), kidney disease (OR  
179 4.96, 95% CI 1.91 – 12.85,  $p < 0.001$ ), osteoporosis (OR 4.66, 95% CI 1.76 – 12.33,  $p = 0.002$ ) and  
180 rheumatoid arthritis (OR 4.55, 95% CI 2.33 – 8.88,  $p < 0.001$ ). Neither regression model showed any  
181 condition to be significantly lower odds in the autism group.

182 [Insert Table 2]

### 183 *Intellectual Disability Sub-analysis*

184 In the ID sub-analysis logistic regression model, most conditions had similar odds ratios in both the  
185 isolated autism sample and the autism and ID sample (Table 3, Figure 1), however, fewer results  
186 reached significance in the ID subgroup. Several conditions demonstrated larger odds ratios in the  
187 autism and ID group (Figure 1). These included head injury (OR 8.11, 95% CI 2.51 – 26.26), liver  
188 disease (OR 22.28, 95% CI 3.75 – 132.51), osteoporosis (OR 29.54, 95% CI 6.20 – 140.64) and  
189 hyperthyroidism (13.89, 95% CI 2.36 – 81.99).

190 [Insert Table 3]

191 [Insert Figure 1]

192 **Discussion**

193 In this study, we investigated the prevalence of physical health conditions in autism compared to a  
194 control sample without autism or mental health conditions. The results suggest that autistic  
195 individuals are at an increased risk of a range of physical health conditions compared to non-autistic  
196 individuals, across multiple organ systems, and the risk for some conditions is elevated in individuals  
197 with ID. This continues into older adulthood, with diagnoses such as osteoporosis and dementia  
198 being significantly more common in autistic individuals. Such findings are in keeping with results of  
199 previous studies which also find increased odds of a range of physical health conditions in autism,  
200 and here we add to that literature with novel associations with previously unstudied physical health  
201 conditions<sup>6–9</sup>.

202 In accordance with existing research, our study found increased odds of epilepsy in autism, however,  
203 the aOR of 3.44 was lower than reported in previous studies<sup>7,8,11,13</sup>. This may be accounted for by an  
204 unusually high frequency of epilepsy in the control sample (1.8% compared to an estimated 0.4–  
205 1.0% in the general population<sup>32</sup>), likely due to ascertainment and self-selection bias present in the  
206 wider NCMH database recruitment. It is difficult to compare to previous literature, as studies are  
207 heterogenous in their definition of epilepsy, ranging from strict international criteria to simply >1  
208 seizure, and in this study, the questionnaire reported data on ‘epilepsy/seizure disorder’, which  
209 could be interpreted by participants to include non-epileptic seizure disorders. Despite this, this  
210 study and findings from existing research support the conclusion that epilepsy is significantly more  
211 common in autism. This study also recorded an increased risk of migraine headaches, which mirrors  
212 findings by Underwood et al<sup>33</sup> in an earlier, smaller sample of this cohort and similar findings in other  
213 studies<sup>10,13,29</sup>, though not all find a significant association<sup>7,11,12</sup>. Taken in combination, the results are  
214 in keeping with Pan et al<sup>13</sup> and Ward et al’s<sup>10</sup> findings of increased neurological disorders in autism.

215 Our findings strongly support increased odds of liver and kidney disease in autistic individuals, with a  
216 nearly 11-fold and 5-fold increased risk respectively, however, existing research on these diseases is  
217 sparse. Renal disease shows a slightly increased odds in autism in Croen et al’s study<sup>7</sup> (aOR 1.26, 99%  
218 CI 1–1.59) while Liu et al finds no increased risk<sup>9</sup>, but studies are few. Hepatic disease shows a non-  
219 significant increased odds in autistic adults in Croen et al’s study (aOR 1.58, 99% CI 0.96–2.60)<sup>7</sup>,  
220 while Shedlock et al found autistic children were more likely than controls to have non-alcoholic  
221 fatty liver disease/steatohepatitis (OR 2.74, 95% CI 2.06–3.65)<sup>20</sup>. A recent study by Ward et al finds  
222 increased odds of hepatic/renal disease in autistic participants<sup>10</sup>, while Schott et al find decreased  
223 odds of hepatic (OR 0.87 99% CI 0.83–0.91) and renal (OR 0.82 99% CI 0.80–0.84) disorders<sup>12</sup>. The  
224 current results suggest liver and kidney disease may be much more common in the autistic



225 community, but further investigation is required to examine whether this replicates across the  
226 autistic population or could be accounted for by confounders in our sample.

227 This analysis also found a trend towards increased metabolic diseases in autism, with increased odds  
228 of type 2 diabetes, elevated lipids and hypertension. This echoes findings by Shedlock et al<sup>20</sup> of  
229 increased prevalence of obesity, type 2 diabetes, hypertension, hyperlipidaemia and fatty liver  
230 disease in autistic children. Indeed, the findings of increased hypertension and hyperlipidaemia fit  
231 with most previous findings on these conditions<sup>7,8,11,12,14,20</sup>, suggesting they are more common in  
232 autism, however, it is difficult to make conclusions about type 2 diabetes, given the mixed findings in  
233 existing literature. This study lacked obesity data, but obesity rates may also be higher in  
234 autism<sup>9,12,20,34</sup>, leading to questions of whether the increased prevalence of these conditions is driven  
235 by diet and weight, or if independent mechanisms are at play.

236 The lack of significant findings for type 1 diabetes contrasted other autoimmune conditions, where  
237 we found increased odds in the autistic cohort, including rheumatoid arthritis, 'other autoimmune  
238 disease' and hypothyroidism (which although not exclusively autoimmune in aetiology, is often  
239 commonly caused by autoimmune disease). Overall, we add to the picture that autoimmune  
240 diseases are more prevalent in autism<sup>7,23,24</sup>, though specifics of individual autoimmune conditions  
241 are still unclear.

242 Findings of significantly increased odds of osteoarthritis, osteoporosis and nominally significant  
243 increased odds of memory loss/dementia were in keeping with Croen et al's findings on dementia<sup>7</sup>  
244 and Hand et al's/Liu et al's findings of an increased risk of a range of age-related health conditions,  
245 including osteoarthritis<sup>9</sup>, osteoporosis, and cognitive disorders<sup>8</sup>. Some researchers theorise that  
246 there may be overlapping pathophysiology between autism and neurodegenerative conditions like  
247 dementia and Parkinson's, including genetic commonalities, defects in neurotransmitters common  
248 to both conditions and changes in beta-amyloid seen in autism that may predispose to Alzheimer's<sup>35</sup>.  
249 This research is in its infancy and many of the proposed mechanisms are currently theoretical, but it  
250 may in time yield concrete evidence of shared predisposing mechanisms. Few studies on physical  
251 health consider the older autistic population, despite many conditions increasing in prevalence with  
252 age, or only occurring in older individuals. This study had a relatively small sample of over-50s in the  
253 autism sample (91 individuals, 14.4% of the sample), but its findings provide support to the small  
254 number of existing studies and suggest this is an area requiring substantial further investigation, as  
255 greater numbers of autistic older adults are identified, potentially including longitudinal studies into  
256 older adulthood.

257 Several findings in this study were novel. The study found increased odds of gastric/duodenal ulcers  
258 (aOR 2.37, 95% CI 1.18–4.76), which has not been documented to the authors knowledge in existing  
259 literature. This finding may relate to autistic behaviours, and therefore the potential impact of diet  
260 and medications like non-steroidal anti-inflammatories on this relationship would be an interesting  
261 area for future exploration. Head injury is also not specifically explored in any existing  
262 epidemiological literature, despite being associated with autism<sup>36</sup>. This study finds significantly  
263 increased odds of it in autism (aOR 3.84, 95% CI 2.30–6.39). Exploration of the nature of head  
264 injuries and the cause behind them (e.g. behavioural, neurological/motor deficits, self-injury) is  
265 warranted.

266 For some conditions, no significant association with autism was found. Breast cancer, cancer and  
267 heart disease did not show significant differences in odds ratios in our sample. Research on these  
268 conditions is mixed with studies finding both higher<sup>8,29</sup>, lower<sup>11,12</sup> and non-significant<sup>7</sup> odds of cancer  
269 compared to controls, and studies finding higher odds<sup>7–9,21</sup> or no difference<sup>9,14,22</sup> in heart disease in  
270 autism. This study also found no significant difference in stroke between groups, despite findings of  
271 increased odds in three previous studies<sup>7–9</sup>. Other conditions, including multiple sclerosis,  
272 Parkinson’s disease and HIV had low absolute prevalence in the dataset such that they are  
273 underpowered to detect any differences between groups, and we cannot comment on their  
274 prevalence in autism.

275 Though we could not do a direct comparison between individuals with and without ID, we observed  
276 that for osteoporosis, hyperthyroidism, liver disease and head injury, there are larger odds relative  
277 to the control group in the group with concurrent ID compared to the autistic group without ID. This  
278 suggests this population may be at increased risk of these conditions, however confidence intervals  
279 for both groups overlapped. Several systematic reviews conclude that epilepsy prevalence in autism  
280 is higher in those with concurrent ID<sup>15,16</sup> and one study into over-65s found increased odds of several  
281 conditions including osteoporosis, epilepsy, gastrointestinal disorders, thyroid disorders and  
282 cognitive disorders<sup>37</sup>. Another study, however, found the risk of most physical health conditions  
283 compared to non-autistic individuals was similar in autistic adults with and without ID<sup>9</sup>. This is a  
284 relative new area of study limiting the ability to draw conclusions especially given the size of our  
285 sample, however these early results suggest that concurrent ID could confer increased risk for  
286 certain physical conditions.

287 The mechanisms underpinning increased physical health problems in autism are likely multifactorial,  
288 involving shared aetiological factors, genetic influences and differences in behaviour and lifestyle. It  
289 is possible that barriers to accessing appropriate healthcare, such as communication difficulties,

290 different symptom presentation and sensitivity to examinations or healthcare settings, may limit  
291 preventative care, leading to a greater development of chronic disease in this population. Poor diet  
292 and exercise, which can be a result of behavioural restriction, food hypersensitivities, social  
293 difficulties, and comorbid motor/nervous conditions, may be another contributing mechanism. Weir  
294 et al<sup>38</sup> found autistic individuals were less likely to meet recommendations for diet and exercise on  
295 most measures and more likely to be underweight or obese than controls. These may increase the  
296 risk of a variety of negative health outcomes e.g. cardiovascular disease. For epilepsy, there are  
297 many studies that evidence areas of overlap between the two conditions. This includes findings of  
298 dysfunction in GABA signalling and circuitry, common associated genes and abnormal grey-white  
299 matter volumes in both autism and epilepsy<sup>39</sup>. A hypothesised biological mechanism underpinning  
300 both conditions may be one of excitation-inhibition imbalance in the neural circuitry, leading to  
301 hyperexcitability, with different genetic or neurodevelopmental changes found to be common to  
302 both epilepsy and autism converging to cause this imbalance<sup>39</sup>. It is possible that other shared  
303 mechanisms may exist but are yet to be determined.

#### 304 *Limitations*

305 This was an analysis of existing data, collected over several years using iteratively updated  
306 questionnaires. Several physical health outcomes, including COPD, head injury, HIV, meningitis, IBD  
307 and 'other autoimmune disease' were not present in the earliest versions of the NCMH  
308 questionnaire meaning these had more missing data (20.2-20.7%) compared to other variables (0.6-  
309 1.3%). Furthermore, missing data in these variables was overrepresented in autism (~50% missing  
310 data, compared to ~12% in the control sample). Thus, the findings on these conditions are less  
311 reliable and must be taken with more caution.

312 Additional factors limited the generalisability and interpretation of our findings. Rates of physical  
313 health conditions in control individuals in the NCMH database may differ from the wider general  
314 population, as evidenced by the elevated rate of epilepsy in controls here. This may be due to  
315 ascertainment bias through recruitment from healthcare environments such as NHS waiting rooms,  
316 and self-selection bias for individuals with health concerns. Secondly, some lifestyle factors that  
317 could affect physical health in autism, like BMI and alcohol use, could not be controlled for. Meta-  
318 analytic evidence suggests that rates of obesity are significantly higher in autism<sup>34</sup> and thus obesity,  
319 which is a risk factor for a variety of conditions, could be a confounder of the relationship found  
320 between autism and physical health. Other variables, like smoking, had differing responses between  
321 questionnaire versions, with some versions quantifying smoking, while others only asked about

322 smoking as a binary yes or no. For consistency, this study recorded smoking as a binary yes/no, taken  
323 from 'lifetime ever smoked', and this may miss the full effect of smoking on physical health.

324 Furthermore, our control sample was defined by lack of mental health conditions, meaning it is not  
325 fully reflective of the general population and despite knowledge that among the autistic community  
326 there is a high burden of co-occurring mental health conditions, like ADHD, anxiety disorders and  
327 depressive disorders<sup>4</sup>, our study could not control for the effects of these on physical health  
328 outcomes. In addition, clinical notes were not available to confirm diagnoses, so the study relies on  
329 self-report of clinician diagnosis, which reduces the reliability of our estimates.

330 Our autistic group had a much lower mean age and had only a limited number of individuals over 50,  
331 which may explain the higher rates of cancer, heart disease, hypertension and osteoarthritis in the  
332 control group found in the initial Chi-squared analysis. Though statistical modelling allowed us to  
333 control for the effects of age, the lack of older autistic individuals for comparison may mean we are  
334 missing the full picture around the occurrence of conditions that are more common with age.

335

336 Though the overall sample size in our study was not small, it was still small enough that rarer  
337 conditions with lower prevalences had too few cases for comparison, and our sample size was  
338 smaller than many comparable studies looking at a range of comorbidities<sup>6-9,11,12</sup>. Autistic and  
339 control samples were not matched on variables such as age and sex in an attempt to maximise  
340 sample size for testing. This introduced additional issues, as controlling for variables such as age and  
341 sex is not optimal, and likely introduce biases. Furthermore, the high percentage of females in the  
342 control group (65.8%) as well as the higher percentage of females and lower percentage of  
343 individuals with ID in the autistic group than would typically be expected does raise questions over  
344 the representativeness of our sample, and again point towards ascertainment, response and self-  
345 selection biases<sup>40</sup>.

346 Sub-analysis was limited by the small sample of autistic individuals with ID. Our sample included only  
347 86 in this group, with some conditions including less than 30 recorded responses. Several conditions  
348 had no cases or too few cases in this population for meaningful analysis. It is also likely that there is a  
349 selection bias away from individuals with intellectual disabilities in the wider NCMH sample,  
350 particularly those that are more severe, as several of the recruitment methods and the use of  
351 written questionnaires may better suit those without ID. To combat this, NCMH has been  
352 undertaking targeted recruitment within the ID community using appropriately adapted measures.  
353 Ultimately, concerns around size and representativeness of our sample for sub-analysis limits any

354 conclusions we can make and emphasises that research into the experiences of individuals with ID is  
355 under-researched and under-represented in the literature.

### 356 *Clinical implications and future directions*

357 This study draws attention to the increased physical health burden experienced by the autistic  
358 community and adds to a growing field of research in this area with novel associations. This  
359 increased health burden is likely to have wide-ranging impacts on quality of life and mental health  
360 and may contribute to a risk of premature mortality in autism<sup>41</sup>. It is vital that research is carried out  
361 in all demographics of the autistic community as some groups, for example older individuals (>50) or  
362 those with concurrent ID, are harder to sample and at risk of involuntary exclusion whilst also being  
363 more at risk. Further investigations are required to begin to understand the mechanisms behind the  
364 higher rates of physical health conditions observed in autistic individuals, alongside any mediating  
365 factors, with the aim of developing intervention and prevention strategies. Furthermore, there may  
366 be a role for enhanced health screening in autistic individuals, and future research should identify  
367 the value and focus of such screening. It is hoped that it will increase awareness among healthcare  
368 professionals of physical health in autism and encourage clinicians to have a lower threshold for  
369 considering physical illness when individuals present with changes in behaviour, as well as physical  
370 signs.

### 371 **Declaration of Interest: None**

### 372 **Author details**

373 Megan Hunt\* - Foundation Year 1 Doctor, North Bristol NHS Trust, Bristol, UK, & Neuroscience &  
374 Mental Health Innovation Institute, Division for Psychological Medicine and Clinical Neuroscience,  
375 Cardiff University, UK

376 Jack F G Underwood\*- Wellcome GW4-CAT Clinical Research Fellow, Neuroscience & Mental Health  
377 Innovation Institute, Division for Psychological Medicine and Clinical Neuroscience, Cardiff  
378 University, UK

379 Leon Hubbard – Data Manager, National Centre for Mental Health, Division for Psychological  
380 Medicine and Clinical Neuroscience, Cardiff University, UK

381 Jeremy Hall – Hodge Professor of Neuroscience, Neuroscience & Mental Health Innovation Institute,  
382 Division for Psychological Medicine and Clinical Neuroscience, Cardiff University, UK

383 \*Indicates joint first author

384 Correspondence to Jack Underwood, [underwoodj4@cardiff.ac.uk](mailto:underwoodj4@cardiff.ac.uk)

385 ***Author contributions***

386 JH and JU conceptualised and designed the study. LH acquired and performed initial processing on  
387 data from the NCMH database. MH and JU formulated the statistical plan and ran analyses on the  
388 data. MH and JU wrote the first draft of the manuscript. All authors contributed to revisions of the  
389 paper prior to submission.

390 **Data Availability Statement**

391 The data that support the findings of this study are available on request from the corresponding  
392 author, JFGU. The data are not publicly available due to NCMH ethics and data management  
393 requirements.

394 **Acknowledgements**

395 The authors would like to thank the NCMH team for their support with the data for the project. The  
396 National Centre for Mental Health (NCMH) is a collaboration between Cardiff, Swansea and Bangor  
397 Universities and is funded by Welsh Government through Health and Care Research Wales. We  
398 thank the NCMH study participants for their invaluable contribution to this project.

399 **Funding**

400 This publication is the work of the authors and Jack F G Underwood and Megan Hunt will serve as  
401 guarantors for the contents of this paper. This research was funded in whole, or in part, by the  
402 Wellcome Trust, through a GW4-CAT Clinical Doctoral Fellowship to J.F.G.U. (222849/Z/21/Z). JH and  
403 JFGU are supported by Healthcare Research Wales through the National Centre for Mental Health  
404 (NCMH) and an MRC Pathfinder Grant (MC\_PC\_17212). JH was also supported by the Waterloo  
405 Foundation Future Minds Programme. For the purpose of Open Access, the author has applied a CC  
406 BY public copyright licence to any Author Accepted Manuscript version arising from this submission.  
407 The funding organisations had no role in the design and conduct of the study; collection,  
408 management, analysis and interpretation of the data; preparation, review or approval of the  
409 manuscript; and decision to submit the manuscript for publication.

410 **References**

- 411 1. Bottema-Beutel K, Kapp SK, Lester JN, Sasson NJ, Hand BN. Avoiding Ableist Language:  
412 Suggestions for Autism Researchers. *Autism Adulthood*. 2021 Mar 1;3(1):18–29.
- 413 2. Fombonne E, MacFarlane H, Salem AC. Epidemiological surveys of ASD: advances and  
414 remaining challenges. *J Autism Dev Disord*. 2021;51(12):4271–90.

- 415 3. Loomes RDC, Hull LMs, Mandy WPLDCP. What is the Male-to-Female Ratio in Autism  
416 Spectrum Disorder? A Systematic Review and Meta-Analysis. *J Am Acad Child Adolesc Psychiatry*.  
417 2017;56(6):466–74.
- 418 4. Hossain MM, Khan N, Sultana A, Ma P, McKyer ELJ, Ahmed HU, et al. Prevalence of comorbid  
419 psychiatric disorders among people with autism spectrum disorder: An umbrella review of  
420 systematic reviews and meta-analyses. *Psychiatry Res*. 2020;287:112922–112922.
- 421 5. Rydzewska E, Dunn K, Cooper SA. Umbrella systematic review of systematic reviews and  
422 meta-analyses on comorbid physical conditions in people with autism spectrum disorder. *Br J*  
423 *Psychiatry*. 2021;218(1):10–9.
- 424 6. Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L, et al. The co-  
425 morbidity burden of children and young adults with autism spectrum disorders. *PloS One*.  
426 2012;7(4):e33224–e33224.
- 427 7. Croen LA, Zerbo O, Qian Y, Massolo ML, Rich S, Sidney S, et al. The health status of adults on  
428 the autism spectrum. *Autism*. 2015 Oct 1;19(7):814–23.
- 429 8. Hand BN, Angell AM, Harris L, Carpenter LA. Prevalence of physical and mental health  
430 conditions in Medicare-enrolled, autistic older adults. *Autism Int J Res Pract*. 2020;24(3):755–64.
- 431 9. Liu S, Larsson H, Kuja-Halkola R, Lichtenstein P, Butwicka A, Taylor MJ. Age-related physical  
432 health of older autistic adults in Sweden: a longitudinal, retrospective, population-based cohort  
433 study. *Lancet Healthy Longev*. 2023;4(7):e307–15.
- 434 10. Ward JH, Weir E, Allison C, Baron-Cohen S. Increased rates of chronic physical health  
435 conditions across all organ systems in autistic adolescents and adults. *Mol Autism*. 2023 Sep  
436 20;14(1):35.
- 437 11. Vohra R, Madhavan S, Sambamoorthi U. Comorbidity prevalence, healthcare utilization, and  
438 expenditures of Medicaid enrolled adults with autism spectrum disorders. *Autism Int J Res Pract*.  
439 2017 Nov;21(8):995–1009.
- 440 12. Schott W, Tao S, Shea L. Co-occurring conditions and racial-ethnic disparities: Medicaid  
441 enrolled adults on the autism spectrum. *Autism Res Off J Int Soc Autism Res*. 2022 Jan;15(1):70–85.
- 442 13. Pan PY, Bölte S, Kaur P, Jamil S, Jonsson U. Neurological disorders in autism: A systematic  
443 review and meta-analysis. *Autism Int J Res Pract*. 2021;25(3):812–30.
- 444 14. Tyler CV, Schramm SC, Karafa M, Tang AS, Jain AK. Chronic disease risks in young adults with  
445 autism spectrum disorder: Forewarned is forearmed. *Am J Intellect Dev Disabil*. 2011;116(5):371–80.
- 446 15. Woolfenden SUE, Sarkozy V, Ridley G, Coory M, Williams K. A systematic review of two  
447 outcomes in autism spectrum disorder - epilepsy and mortality. *Dev Med Child Neurol*.  
448 2012;54(4):306–12.
- 449 16. Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, Lechat P, et al. Epilepsy in  
450 Autism is Associated with Intellectual Disability and Gender: Evidence from a Meta-Analysis. *Biol*  
451 *Psychiatry* 1969. 2008;64(7):577–82.
- 452 17. McElhanon BO, McCracken C, Karpen S, Sharp WG. Gastrointestinal symptoms in autism  
453 spectrum disorder: A meta-analysis. *Pediatr Evanst*. 2014;133(5):872–83.

- 454 18. Lee M, Krishnamurthy J, Susi A, Sullivan C, Gorman GH, Hisle-Gorman E, et al. Association of  
455 Autism Spectrum Disorders and Inflammatory Bowel Disease. *J Autism Dev Disord.* 2017;48(5):1523–  
456 9.
- 457 19. Doshi-Velez F, Avillach P, Palmer N, Bousvaros A, Ge Y, Fox K, et al. Prevalence of  
458 Inflammatory Bowel Disease among Patients with Autism Spectrum Disorders. *Inflamm Bowel Dis.*  
459 2015;21(10):2281–8.
- 460 20. Shedlock KMD, Susi AMS, Gorman GHMD, Hisle-Gorman EP, Erdie-Lalena CRMD, Nylund  
461 CMMD. Autism Spectrum Disorders and Metabolic Complications of Obesity. *J Pediatr.*  
462 2016;178:183-187.e1.
- 463 21. Weir E, Allison C, Warriar V, Baron-Cohen S. Increased prevalence of non-communicable  
464 physical health conditions among autistic adults. *Autism Int J Res Pract.* 2021;25(3):681–94.
- 465 22. Mouridsen SE, Rich B, Isager T. Diseases of the circulatory system among adult people  
466 diagnosed with infantile autism as children: A longitudinal case control study. *Res Dev Disabil.*  
467 2016;57:193–200.
- 468 23. Zerbo O, Leong A, Barcellos L, Bernal P, Fireman B, Croen LA. Immune mediated conditions  
469 in autism spectrum disorders. *Brain Behav Immun.* 2015;46:232–6.
- 470 24. Spann MN, Timonen-Soivio L, Suominen A, Cheslack-Postava K, McKeague IW, Sourander A,  
471 et al. Proband and Familial Autoimmune Diseases Are Associated With Proband Diagnosis of Autism  
472 Spectrum Disorders. *J Am Acad Child Adolesc Psychiatry.* 2019;58(5):496–505.
- 473 25. Brooks JD, Bronskill SE, Fu L, Saxena FE, Arneja J, Pinzaru VB, et al. Identifying Children and  
474 Youth With Autism Spectrum Disorder in Electronic Medical Records: Examining Health System  
475 Utilization and Comorbidities. *Autism Res.* 2021 Feb 1;14(2):400–10.
- 476 26. Zheng Z, Zhang L, Zhu T, Huang J, Qu Y, Mu D. Association between asthma and autism  
477 spectrum disorder: A meta-analysis. *PloS One.* 2016;11(6):e0156662–e0156662.
- 478 27. Kaas TH, Vinding RK, Stokholm J, Bønnelykke K, Bisgaard H, Chawes BL. Association between  
479 childhood asthma and attention deficit hyperactivity or autism spectrum disorders: A systematic  
480 review with meta-analysis. *Clin Exp Allergy.* 2020;51(2):228–52.
- 481 28. Tromans S, Yao G, Alexander R, Mukaetova-Ladinska E, Kiani R, Al-Uzri M, et al. The  
482 Prevalence of Diabetes in Autistic Persons: A Systematic Review. *Clin Pract Epidemiol Ment Health*  
483 *CP EMH.* 2020;16:212–25.
- 484 29. Alabaf S, Gillberg C, Lundström S, Lichtenstein P, Kerekes N, Råstam M, et al. Physical health  
485 in children with neurodevelopmental disorders. *J Autism Dev Disord.* 2018;49(1):83–95.
- 486 30. Laura Bunting. NCMH Standard Operating Procedure. NCMH; 2018. (Publication Policy).
- 487 31. IBM Corp. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp; 2020.
- 488 32. WHO. Epilepsy. 2022.
- 489 33. Underwood JFG, Kendall KM, Berrett J, Lewis C, Anney R, van den Bree MBM, et al. Autism  
490 spectrum disorder diagnosis in adults: phenotype and genotype findings from a clinically derived  
491 cohort. *Br J Psychiatry.* 2019;215(5):647–53.



492 34. Zheng Z, Zhang L, Li S, Zhao F, Wang Y, Huang L, et al. Association among obesity, overweight  
493 and autism spectrum disorder: A systematic review and meta-analysis. *Sci Rep.* 2017;7(1):11697–9.

494 35. Giorgia Guglielmi. The search for a link between autism and neurodegenerative conditions.  
495 2021;

496 36. Haarbauer-Krupa J, Lee AH, Bitsko RH, Zhang X, Kresnow-Sedacca M jo. Prevalence of  
497 Parent-Reported Traumatic Brain Injury in Children and Associated Health Conditions. *JAMA Pediatr.*  
498 2018;172(11):1078–86.

499 37. Gilmore D, Harris L, Longo A, Hand BN. Health status of Medicare-enrolled autistic older  
500 adults with and without co-occurring intellectual disability: An analysis of inpatient and institutional  
501 outpatient medical claims. *Autism.* 2021 Jan 1;25(1):266–74.

502 38. Weir E, Allison C, Ong KK, Baron-Cohen S. An investigation of the diet, exercise, sleep, BMI,  
503 and health outcomes of autistic adults. *Mol Autism.* 2021;12(1):31–31.

504 39. Bozzi Y, Provenzano G, Casarosa S. Neurobiological bases of autism–epilepsy comorbidity: a  
505 focus on excitation/inhibition imbalance. *Eur J Neurosci.* 2018 Mar 1;47(6):534–48.

506 40. Cheung KL, ten Klooster PM, Smit C, de Vries H, Pieterse ME. The impact of non-response  
507 bias due to sampling in public health studies: A comparison of voluntary versus mandatory  
508 recruitment in a Dutch national survey on adolescent health. *BMC Public Health.* 2017 Mar  
509 23;17(1):276.

510 41. O’Nions E, Lewer D, Petersen I, Brown J, Buckman JEJ, Charlton R, et al. Estimating life  
511 expectancy and years of life lost for autistic people in the UK: a matched cohort study. *Lancet Reg*  
512 *Health – Eur.* 2024;36.

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528  
 529  
 530  
 531  
 532  
 533

**Table 1** Frequency of physical health conditions in cases and controls and the results of Chi-squared analysis

Physical health condition	Frequency - N (%)		Pearson Chi-Squared Value	P value
	Autism	Controls		
<b>Asthma</b>	264 (33.2)	453 (16.3)	108.902	<0.001*
<b>Breast Cancer</b>	0 (0.0)	56 (2.0)		
<b>Cancer (Other)</b>	11 (1.4)	175 (6.3)	30.741	<0.001*
<b>COPD</b>	4 (1.0)	29 (1.2)	0.178	0.673
<b>Diabetes Type 1</b>	7 (0.9)	20 (0.7)	0.199	0.656
<b>Diabetes Type 2</b>	35 (4.4)	128 (4.6)	0.082	0.775
<b>Elevated Lipids/ Cholesterol</b>	72 (9.0)	252 (9.1)	0.003	0.959
<b>Epilepsy/Seizure Disorder</b>	63 (8.0)	50 (1.8)	76.301	<0.001*
<b>Gastric/Duodenal Ulcers</b>	28 (3.5)	68 (2.4)	2.833	0.092
<b>Head Injury</b>	68 (16.4)	79 (3.2)	125.765	<0.001*
<b>Heart disease</b>	12 (1.5)	110 (4.0)	11.290	<0.001*
<b>Hypertension</b>	95 (12.0)	464 (16.7)	10.595	0.001*
<b>Kidney Disease</b>	13 (1.6)	36 (1.3)	0.508	0.476
<b>Liver disease</b>	15 (1.9)	12 (0.4)	17.369	<0.001*
<b>Memory Loss (Dementia)</b>	10 (1.3)	17 (0.6)	3.511	0.061
<b>Migraine Headaches</b>	262 (33.2)	428 (15.5)	123.641	<0.001*
<b>Meningitis</b>	6 (1.4)	21 (0.9)	1.220	0.269
<b>Osteoarthritis</b>	44 (5.5)	247 (8.9)	9.371	0.002*
<b>Osteoporosis</b>	14 (1.8)	54 (1.9)	0.127	0.722
<b>Rheumatoid Arthritis</b>	26 (3.3)	73 (2.6)	0.981	0.322
<b>Stroke/ Haemorrhage</b>	11 (1.4)	39 (1.4)	0.002	0.968
<b>Overactive</b>	6 (0.8)	46 (1.7)	3.458	0.063
<b>Thyroid/Hyperthyroid</b>				
<b>Underactive</b>	40 (5.0)	147 (5.3)	0.095	0.758
<b>Thyroid/Hypothyroid</b>				
<b>Inflammatory Bowel Disease</b>	30 (7.2)	75 (3.1)	17.097	<0.001*
<b>Other autoimmune condition</b>	22 (5.2)	54 (2.2)	12.553	<0.001*

534 COPD = chronic obstructive pulmonary disease  
 535 Human immunodeficiency virus, Parkinson’s Disease and multiple sclerosis are not included due to absolute  
 536 frequency counts <5 allowing back-identification, and were not significantly different.  
 537 \* indicates p-values that are significant after Benjamini-Hochberg correction

538  
 539  
 540  
 541

542  
543  
544  
545  
546  
547

**Table 2** –Odds ratios and p-values from binomial logistic regression

Physical health condition	Model 1		Model 2	
	Adjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value
<b>Asthma</b>	2.36 (1.90 - 2.92)	<0.001*	2.36 (1.84 - 3.02)	<0.001*
<b>Cancer (Other)</b>	0.71 (0.34 - 1.47)	0.357	0.54 (0.20 - 1.43)	0.215
<b>COPD</b>	3.31 (0.88 - 12.48)	0.077	7.42 (1.79 - 30.77)	0.006*
<b>Diabetes Type 1</b>	1.22 (0.43 - 3.41)	0.710	0.64 (0.14 - 3.00)	0.573
<b>Diabetes Type 2</b>	2.74 (1.67 - 4.48)	<0.001*	2.32 (1.28 - 4.21)	0.005*
<b>Elevated Lipids/Cholesterol</b>	3.89 (2.68 - 5.66)	<0.001*	2.75 (1.74 - 4.34)	<0.001*
<b>Epilepsy/Seizure Disorder</b>	3.84 (2.35 - 6.29)	<0.001*	3.44 (1.95 - 6.04)	<0.001*
<b>Gastric/Duodenal Ulcers</b>	2.65 (1.47 - 4.77)	0.001*	2.37 (1.18 - 4.76)	0.016*
<b>Head Injury</b>	5.03 (3.30 - 7.67)	<0.001*	3.84 (2.30 - 6.39)	<0.001*
<b>Heart disease</b>	0.91 (0.38 - 2.13)	0.818	0.57 (0.17 - 1.94)	0.367
<b>Hypertension</b>	2.38 (1.72 - 3.28)	<0.001*	2.11 (1.44 - 3.09)	<0.001*
<b>Kidney Disease</b>	4.97 (2.13 - 11.59)	<0.001*	4.96 (1.91 - 12.85)	<0.001*
<b>Liver disease</b>	11.55 (4.36 - 30.60)	<0.001*	10.96 (3.72 - 32.25)	<0.001*
<b>Memory Loss (Dementia)</b>	4.93 (1.80 - 13.51)	0.002*	3.71 (1.13 - 12.22)	0.031
<b>Migraine Headaches</b>	3.66 (2.92 - 4.59)	<0.001*	3.45 (2.66 - 4.48)	<0.001*
<b>Meningitis</b>	0.85 (0.26 - 2.79)	0.783	1.06 (0.28 - 4.01)	0.928
<b>Multiple sclerosis</b>	0.70 (0.08 - 6.07)	0.743	0.00 (0.00)	0.991
<b>Osteoarthritis</b>	2.84 (1.81 - 4.43)	<0.001*	2.59 (1.50 - 4.46)	<0.001*
<b>Osteoporosis</b>	5.16 (2.37 - 11.25)	<0.001*	4.66 (1.76 - 12.33)	0.002*
<b>Rheumatoid Arthritis</b>	3.49 (1.88 - 6.47)	<0.001*	4.55 (2.33 - 8.88)	<0.001*
<b>Stroke/Haemorrhage</b>	1.93 (0.82 - 4.56)	0.134	1.22 (0.39 - 3.83)	0.730
<b>Overactive Thyroid/Hyperthyroid</b>	1.93 (0.74 - 5.02)	0.177	2.11 (0.68 - 6.55)	0.196
<b>Underactive Thyroid/Hypothyroid</b>	2.70 (1.75 - 4.17)	<0.001*	2.18 (1.28 - 3.70)	0.004*
<b>Inflammatory Bowel Disease</b>	2.97 (1.74 - 5.06)	<0.001*	2.10 (1.06 - 4.17)	0.035
<b>Other autoimmune condition</b>	3.79 (2.00 - 7.17)	<0.001*	3.38 (1.60 - 7.15)	0.001*

548 Model 1 controls for age and sex; Model 2 controls for age, sex, antipsychotic use, mood stabiliser use and  
549 smoking status. COPD = chronic obstructive pulmonary disease  
550 \* indicates P-values that are significant after Benjamini-Hochberg correction

551  
552  
553

554  
 555  
 556  
 557  
 558  
 559

**Table 3** – Odds ratios from the sub-analysis for isolated autism and autism with intellectual disability

Physical health condition	Isolated Autism		Autism and ID	
	Adjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
<b>Asthma</b>	2.32 (1.80 – 2.98)	<0.001*	2.94 (1.60 – 5.42)	<0.001*
<b>COPD</b>	7.47 (1.81 – 30.87)	0.005*	0.00 (0.00)	0.999
<b>Diabetes Type 1</b>	0.59 (0.12 – 2.91)	0.516	1.07 (0.10 – 11.43)	0.956
<b>Diabetes Type 2</b>	2.27 (1.24 – 4.15)	0.008*	3.17 (0.86 – 11.76)	0.084
<b>Elevated Lipids/ Cholesterol</b>	2.75 (1.73 – 4.36)	<0.001*	2.73 (0.94 – 7.90)	0.065
<b>Epilepsy/Seizure Disorder</b>	3.36 (1.89 – 5.96)	<0.001*	4.41 (1.41 – 13.82)	0.011*
<b>Gastric/Duodenal Ulcers</b>	2.42 (1.20 – 4.88)	0.013*	1.45 (0.18 – 11.75)	0.729
<b>Head Injury</b>	3.67 (2.19 – 6.17)	<0.001*	8.11 (2.51 – 26.26)	<0.001*
<b>Heart disease</b>	0.60 (0.17 – 2.04)	0.409	0.00 (0.00)	0.997
<b>Hypertension</b>	2.11 (1.44 – 3.11)	<0.001*	2.13 (0.81 – 5.60)	0.124
<b>Kidney Disease</b>	4.89 (1.87 – 12.81)	0.001*	6.22 (0.69 – 55.62)	0.102
<b>Liver disease</b>	10.42 (3.48 – 31.17)	<0.001*	22.28 (3.75 – 132.51)	<0.001*
<b>Migraine Headaches</b>	3.52 (2.70 – 4.58)	<0.001*	2.63 (1.33 – 5.23)	0.006*
<b>Osteoarthritis</b>	2.60 (1.51 – 4.50)	<0.001*	2.33 (0.50 – 10.90)	0.282
<b>Osteoporosis</b>	3.90 (1.41 – 10.81)	0.009*	29.54 (6.20 – 140.64)	<0.001*
<b>Rheumatoid Arthritis</b>	4.37 (2.21 – 8.66)	<0.001*	7.84 (1.66 – 37.04)	0.009*
<b>Stroke/ Haemorrhage</b>	1.16 (0.36 – 3.74)	0.800	2.11 (0.23 – 19.85)	0.512
<b>Overactive Thyroid/Hyperthyroid</b>	1.62 (0.47 – 5.56)	0.444	13.89 (2.36 – 81.99)	0.004*
<b>Underactive Thyroid/Hypothyroid</b>	2.15 (1.26 – 3.66)	0.005*	2.81 (0.77 – 10.33)	0.120
<b>Inflammatory Bowel Disease</b>	2.05 (1.03 – 4.09)	0.042	3.78 (0.70 – 20.39)	0.122

560 \* indicates P-values that are significant after Benjamini-Hochberg correction

561  
 562  
 563  
 564  
 565  
 566  
 567

568

569


570

571

572

573 **Figure 1** – graph showing the odds ratios from sub-analysis for physical conditions in isolated autism or autism  
574 + intellectual disability compared to the control population

575



576

577

578

579